The question comes up constantly, and it deserves a straight answer rather than a definitional shrug: no, ketamine is not a classic psychedelic in the pharmacological sense — and yes, it belongs to the family in every practical sense that matters to a patient. Both halves are true, and the interesting part is what follows from each.
TL;DR Ketamine is a dissociative anaesthetic. It works on the brain's NMDA glutamate receptors, while the classic psychedelics — psilocybin, LSD — work mainly at the serotonin 2A receptor, and MDMA is an entactogen that acts on serotonin, dopamine and noradrenaline release. So the pharmacology says no. But ketamine produces altered perception and dissociation, is delivered through the same model of preparation, supervised dosing and integration, and is discussed at the same conferences, so the field says yes. The distinction that actually changes your options is legal, not chemical: ketamine is a licensed medicine used off-label, and the classic psychedelics are not.
What ketamine actually is
Ketamine has been a hospital anaesthetic since the 1970s and sits on the WHO list of essential medicines. The form used in most depression research is racemic ketamine, a 50:50 mix of two mirror-image molecules, S-ketamine (esketamine) and R-ketamine. Esketamine is one of those two molecules, isolated and developed into an approved nasal-spray medicine, Spravato, with its own EU marketing authorisation for treatment-resistant depression since December 2019. Racemic ketamine has never been approved as an antidepressant anywhere in Europe, so its use for depression is off-label: legal, but outside the licence.
Its mechanism is where the classification argument starts. Ketamine acts on NMDA glutamate receptors, which is thought to trigger downstream changes in mood-regulating circuits — and explains why relief can arrive within hours rather than the weeks conventional antidepressants take. Our ketamine evidence review covers what that effect looks like in trials.
What "psychedelic" usually means
Used strictly, "psychedelic" means the classic serotonergic compounds. Psilocybin is the standard example: a naturally occurring compound converted in the body to psilocin, which acts mainly at the serotonin 2A receptor, given as a purified or synthetic compound in one or two supervised sessions with preparation and integration around them (psilocybin evidence review). LSD works on the same receptor family.
MDMA is already an exception to the strict definition. It is not a classic psychedelic but an entactogen: it increases release of serotonin, dopamine and noradrenaline, tends to reduce fear responses and increase feelings of trust and openness, and in research is given in two or three supervised sessions inside a longer psychotherapy course (MDMA evidence review).
Ketamine is a third category again — a dissociative. Where the classic psychedelics tend to produce perceptual and emotional intensification, dissociation is more often described as detachment: a dreamlike sense of distance from body and surroundings. It is expected during dosing, it is one of the effects clinics monitor for, and it resolves as the drug clears.
| Ketamine | Psilocybin, LSD | MDMA | |
|---|---|---|---|
| Class | Dissociative anaesthetic | Classic serotonergic psychedelics | Entactogen |
| Main target | NMDA glutamate receptors | Serotonin 2A receptor | Serotonin, dopamine and noradrenaline release |
| Legal status in Europe | Licensed anaesthetic; off-label for depression | Controlled; no approved medicine in the EU | Controlled; no approved medicine in the EU |
| Available outside research? | Yes — private clinics in several countries, plus approved esketamine | Only in Switzerland, Germany's two compassionate-use sites and Czechia's framework | Switzerland only |
Why the label matters in practice
If the answer were purely academic, it would not be worth 1,000 words. It matters for three reasons.
Legality. Because racemic ketamine is a licensed anaesthetic, prescribing it off-label for depression is lawful across Europe, which is why a private clinic market exists at all. Psilocybin and MDMA are controlled substances with no general medical route: outside clinical trials, lawful psilocybin treatment exists in exactly three countries and lawful MDMA therapy in one. That is the entire reason ketamine dominates the European treatment landscape — not superior evidence, but a different legal starting point. Our Europe-wide availability map sets out who can access what, and is ketamine therapy legal? covers the ketamine-specific rules country by country.
Evidence. Grouping the compounds together invites the assumption that they share an evidence base. They do not. Ketamine's rapid antidepressant effect after a single intravenous infusion has been replicated since the landmark 2006 trial, confirmed in a Cochrane review, and qualified by the fact that the benefit usually fades within one to two weeks. Esketamine passed a full regulatory programme of roughly 1,800 patients. Psilocybin's Phase 3 programme is only now reporting. Ketamine-assisted psychotherapy — the format most often marketed as "psychedelic therapy" — is promising but under-evidenced, with no large trial cleanly separating the drug effect from the psychotherapy. The comparison between the two ketamine products is in our Spravato vs ketamine guide.
Risk. "Psychedelic" is a description of experience, not a safety category, and ketamine's risks are its own. Repeated or long-term use carries bladder and urinary-tract damage (ketamine uropathy) and a genuine dependence risk, which is why repeated treatment belongs in a monitored clinical setting rather than at home. Those risks do not transfer from the classic psychedelics, and the classic psychedelics' cautions — particularly around a personal or family history of psychosis or bipolar disorder — do not transfer neatly to ketamine either.
So what should you call it?
In a clinic, "dissociative" is the accurate word and the one a psychiatrist is likely to use. In the wider field, ketamine is treated as psychedelic-adjacent, and that is not sloppiness: the delivery model really is shared. Screening for psychiatric and cardiovascular history, supervised dosing with monitoring, a recovery period, no driving for the rest of the day, and structured follow-up describe a ketamine session and a psilocybin session about equally well.
The useful conclusion is to stop asking which box the molecule belongs in and start asking what is actually on offer where you live. If you want the practical answer for your country, our eligibility check runs in your browser and stores nothing, and the directory lists the ketamine and ketamine-assisted psychotherapy clinics we have verified.
Frequently asked questions
Is ketamine a psychedelic drug?
Not in the strict pharmacological sense. Ketamine is a dissociative anaesthetic acting on NMDA glutamate receptors, whereas classic psychedelics such as psilocybin and LSD act mainly at the serotonin 2A receptor. In everyday usage — clinics, conferences, directories — it is grouped with psychedelics because the subjective effects overlap and the treatment model is the same.
Does ketamine cause hallucinations?
The typical experience is dissociation — a detached, dreamlike feeling — along with mild perceptual changes, rather than the vivid visual imagery associated with a full psilocybin or LSD dose. These effects are expected during dosing, are part of what clinical staff monitor, and settle as the drug is metabolised.
Is ketamine the same thing as Spravato?
Related, not the same. Spravato is esketamine, one of the two mirror-image molecules that make up racemic ketamine, developed into an approved nasal spray with its own EU authorisation and its own trial programme. Racemic ketamine is the older generic anaesthetic, used off-label. They differ in approval, setting, monitoring rules and cost — see our side-by-side comparison.
If ketamine is not a psychedelic, why is it in a psychedelic directory?
Because patients are looking for the same thing: a supervised, screened, medically delivered session with a compound that alters consciousness, followed by structured aftercare. Ketamine is the version of that model which is legally available in most of Europe today, so leaving it out would be tidy taxonomy and useless information.
Is ketamine safer than psilocybin because it is a medicine?
Being licensed as an anaesthetic means it has a known, regulated safety profile in that setting — not that it is risk-free as a repeated depression treatment. Common transient effects include dissociation, nausea, and a short-lived rise in blood pressure and heart rate; repeated use adds bladder-damage and dependence risks that require monitoring. Every route needs proper screening; see our clinic-choice guide.
Sources
- EMA: Spravato (esketamine) EPAR
- Zarate et al. (2006), Archives of General Psychiatry — single-infusion ketamine in treatment-resistant depression
- Caddy et al. (2015), Cochrane Database of Systematic Reviews — ketamine and other glutamate receptor modulators for depression
- British Association of Urological Surgeons consensus on ketamine uropathy, BJU International (2024)
- Blossom — compound overviews
- Psychedelic Alpha — worldwide psychedelic laws tracker
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations change; discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.